当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
Cancer Discovery ( IF 29.7 ) Pub Date : 2017-12-01 , DOI: 10.1158/2159-8290.cd-17-0797
Joel D Leverson 1 , Deepak Sampath 2 , Andrew J Souers 1 , Saul H Rosenberg 1 , Wayne J Fairbrother 2 , Martine Amiot 3 , Marina Konopleva 4 , Anthony Letai 5
Affiliation  

Since the discovery of apoptosis as a form of programmed cell death, targeting the apoptosis pathway to induce cancer cell death has been a high-priority goal for cancer therapy. After decades of effort, drug-discovery scientists have succeeded in generating small-molecule inhibitors of antiapoptotic BCL2 family proteins. Innovative medicinal chemistry and structure-based drug design, coupled with a strong fundamental understanding of BCL2 biology, were essential to the development of BH3 mimetics such as the BCL2-selective inhibitor venetoclax. We review a number of preclinical studies that have deepened our understanding of BCL2 biology and facilitated the clinical development of venetoclax.

Significance: Basic research into the pathways governing programmed cell death have paved the way for the discovery of apoptosis-inducing agents such as venetoclax, a BCL2-selective inhibitor that was recently approved by the FDA and the European Medicines Agency. Preclinical studies aimed at identifying BCL2-dependent tumor types have translated well into the clinic thus far and will likely continue to inform the clinical development of venetoclax and other BCL2 family inhibitors. Cancer Discov; 7(12); 1376–93. ©2017 AACR.



中文翻译:

在翻译中找到:临床前研究如何指导BCL2选择性抑制剂Venetoclax的临床开发。

自从发现凋亡是程序性细胞死亡的一种形式以来,靶向凋亡途径以诱导癌细胞死亡一直是癌症治疗的高度优先目标。经过数十年的努力,药物发现科学家成功地产生了抗凋亡BCL2家族蛋白的小分子抑制剂。创新的药物化学和基于结构的药物设计,加上对BCL2生物学的深刻理解,对于开发BH3模拟物(如BCL2选择性抑制剂Venetoclax)至关重要。我们审查了许多临床前研究,这些研究加深了我们对BCL2生物学的理解并促进了venetoclax的临床发展。

启示:对控制程序性细胞死亡的途径的基础研究为发现凋亡诱导剂,如委内瑞拉(venetoclax)铺平了道路,委内瑞拉是一种BCL2选择性抑制剂,最近已获得FDA和欧洲药品管理局的批准。迄今为止,旨在鉴定依赖BCL2的肿瘤类型的临床前研究已经很好地转化为临床,并且可能会继续为Venetoclax和其他BCL2家族抑制剂的临床发展提供信息。巨蟹座Discov; 7(12);1376–93。©2017 AACR。

更新日期:2017-12-05
down
wechat
bug